37 min

Professor Justin Stebbing On Vaccine Breakthroughs And Herd-Immunity By Summer Macro Hive Conversations With Bilal Hafeez

    • Investing

This episode is supported by private equity platform Moonfare.
In this show, I talk with Professor Justin Stebbing. I had him as a guest in July when he argued that we could see a COVID vaccine around US election time. He was right and so I wanted to get his latest views. For background, Justin is a professor in the Faculty of Medicine at Imperial college London. He specializes in cancers and immunotherapies. He has an extensive research background having published over 550 peer-reviewed papers. Earlier this year, he published in the Lancet new research on using AI to find drugs to treat COVID-19 and recently published in Foreign Affairs China’s global role in vaccine distribution. In this podcast we discuss:
The significance of Pfizer’s 90% efficacy rate Vaccines from other pharma companies including from Russia & China The science of vaccines – B-cell and T-cell responses Fast tracking of vaccine approval by FDA Managing public opinion and anti-vaxxers Logistics of vaccine distribution When will we get to herd-immunity Remaining uncertainties around vaccines Mink factories and mutations Long COVID and athletes Which countries have secured vaccine supplies

This episode is supported by private equity platform Moonfare.
In this show, I talk with Professor Justin Stebbing. I had him as a guest in July when he argued that we could see a COVID vaccine around US election time. He was right and so I wanted to get his latest views. For background, Justin is a professor in the Faculty of Medicine at Imperial college London. He specializes in cancers and immunotherapies. He has an extensive research background having published over 550 peer-reviewed papers. Earlier this year, he published in the Lancet new research on using AI to find drugs to treat COVID-19 and recently published in Foreign Affairs China’s global role in vaccine distribution. In this podcast we discuss:
The significance of Pfizer’s 90% efficacy rate Vaccines from other pharma companies including from Russia & China The science of vaccines – B-cell and T-cell responses Fast tracking of vaccine approval by FDA Managing public opinion and anti-vaxxers Logistics of vaccine distribution When will we get to herd-immunity Remaining uncertainties around vaccines Mink factories and mutations Long COVID and athletes Which countries have secured vaccine supplies

37 min